JP5416095B2 - 腎毒性を低めるために有用な組成物及びその使用方法 - Google Patents

腎毒性を低めるために有用な組成物及びその使用方法 Download PDF

Info

Publication number
JP5416095B2
JP5416095B2 JP2010509552A JP2010509552A JP5416095B2 JP 5416095 B2 JP5416095 B2 JP 5416095B2 JP 2010509552 A JP2010509552 A JP 2010509552A JP 2010509552 A JP2010509552 A JP 2010509552A JP 5416095 B2 JP5416095 B2 JP 5416095B2
Authority
JP
Japan
Prior art keywords
mtx
captisol
mice
cyclodextrin
molar ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010509552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010528045A5 (enExample
JP2010528045A (ja
Inventor
ディー． ロウ，バーノン
Original Assignee
バーロウ ファーマシューティカルズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バーロウ ファーマシューティカルズ，インコーポレイティド filed Critical バーロウ ファーマシューティカルズ，インコーポレイティド
Publication of JP2010528045A publication Critical patent/JP2010528045A/ja
Publication of JP2010528045A5 publication Critical patent/JP2010528045A5/ja
Application granted granted Critical
Publication of JP5416095B2 publication Critical patent/JP5416095B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010509552A 2007-05-25 2008-05-22 腎毒性を低めるために有用な組成物及びその使用方法 Active JP5416095B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/753,883 US7658913B2 (en) 2005-11-28 2007-05-25 Compositions useful for reducing nephrotoxicity and methods of use thereof
US11/753,883 2007-05-25
PCT/US2008/064489 WO2008147856A1 (en) 2007-05-25 2008-05-22 Compositions useful for reducing nephrotoxicity and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2010528045A JP2010528045A (ja) 2010-08-19
JP2010528045A5 JP2010528045A5 (enExample) 2011-06-02
JP5416095B2 true JP5416095B2 (ja) 2014-02-12

Family

ID=40076731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010509552A Active JP5416095B2 (ja) 2007-05-25 2008-05-22 腎毒性を低めるために有用な組成物及びその使用方法

Country Status (10)

Country Link
US (5) US7658913B2 (enExample)
EP (1) EP2162138B1 (enExample)
JP (1) JP5416095B2 (enExample)
KR (1) KR20100023901A (enExample)
CN (1) CN101686991A (enExample)
AU (1) AU2008256808B2 (enExample)
BR (1) BRPI0812166A2 (enExample)
CA (1) CA2687574C (enExample)
MX (1) MX2009012523A (enExample)
WO (1) WO2008147856A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658913B2 (en) * 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
CN101686681B (zh) 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
PL3100728T3 (pl) 2009-05-13 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania
EP2854531A4 (en) * 2012-05-30 2016-03-23 Verrow Pharmaceuticals Inc STABILIZED FORMULATIONS WITH IODIC CONTRASTIVE AND CYCLODEXTRINS
JP6239282B2 (ja) * 2013-06-28 2017-11-29 日本食品化工株式会社 腎不全改善剤
WO2015147018A1 (ja) * 2014-03-28 2015-10-01 テルモ株式会社 炎症性自己免疫疾患治療用の注射用水性製剤
CN104280478B (zh) * 2014-11-03 2016-03-30 天津中医药大学 内源性小分子物质在快速检测肾毒性方面的应用
EP3313519B1 (en) 2015-06-29 2023-05-31 Children's Medical Center Corporation Jak-stat inhibitors for the treatment of congenital myopathies
MX2019013053A (es) * 2017-05-03 2020-02-07 Cydex Pharmaceuticals Inc Composicion que contiene ciclodextrina y busulfan.
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
CN114982708A (zh) * 2022-05-11 2022-09-02 成都医学院第一附属医院 一种小鼠造影剂肾病模型及其构建方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US4247535A (en) 1979-11-05 1981-01-27 American Cyanamid Company Modified cyclodextrin sulfate salts as complement inhibitors
US4371673A (en) 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4654325A (en) 1984-05-24 1987-03-31 Selenke William M Medicament for reducing nephrotoxicity caused by positively charged agents such as aminoglycosides and methods of use thereof
IL76889A0 (en) 1984-11-02 1986-02-28 Johnson Matthey Plc Solubilised platinum compound,method for the production thereof and pharmaceutical compositions containing the same
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
WO1988003923A1 (fr) * 1986-11-25 1988-06-02 Institut Organicheskogo Sinteza Akademii Nauk Latv Guanines substitutees en position 9
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US5441944A (en) 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
US5010092A (en) * 1989-12-22 1991-04-23 Wisconsin Alumni Research Foundation Protection against chemically-induced kidney damage by methimazole
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
AU6818094A (en) 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US6540981B2 (en) * 1997-12-04 2003-04-01 Amersham Health As Light imaging contrast agents
US5906981A (en) * 1996-06-04 1999-05-25 Troy Corporation Halopropargyl inclusion complexes
US5780446A (en) 1996-07-09 1998-07-14 Baylor College Of Medicine Formulations of vesicant drugs and methods of use thereof
FR2754270B1 (fr) 1996-10-07 1998-12-24 Goemar Lab Sa Genes codant pour des iota-carraghenases et leur utilisation pour la production d'enzymes de biodegradation des carraghenanes
ATE308337T1 (de) 1997-03-15 2005-11-15 Nakamura Toshikazu Hgf zur behandlung von akutem nierenversagen
JPH11100401A (ja) 1997-07-30 1999-04-13 Kikkoman Corp 環状オリゴ糖及びそれを含むレトロウイルス性疾患の予防または治療剤
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
JP3229286B2 (ja) * 1999-04-02 2001-11-19 インターナショナル・ビジネス・マシーンズ・コーポレーション プリント回路基板の製造方法
US6984632B1 (en) * 1999-07-01 2006-01-10 Italfarmaco S.P.A. Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives
GB9921954D0 (en) 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
GB9921958D0 (en) 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
KR100358855B1 (ko) * 2000-02-29 2002-10-31 광주과학기술원 사이클로덱스트린 또는 그 유도체와 조영제의 포접 착체형성 방법
KR100362080B1 (ko) 2000-03-29 2002-11-23 광주과학기술원 고리 올리고당과 그들의 유도체를 이용한 조영제의 새로운포접 착체
DE60136926D1 (de) 2000-05-02 2009-01-22 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
WO2002089805A2 (en) 2001-05-03 2002-11-14 Midamerica Neuroscience Research Foundation Use of regularly scheduled high dose intravenous methotrexate therapy
ITMI20012749A1 (it) * 2001-12-21 2003-06-21 Chiesi Farma Spa Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut
US20030220294A1 (en) * 2002-03-21 2003-11-27 Wallace Kendall B. Cyclodextrin compositions and methods of treating viral infections
EP1556033A4 (en) 2002-05-17 2006-05-31 Celgene Corp METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
US20040048871A1 (en) 2002-09-09 2004-03-11 Rowe Vernon D. Use of high dose intravenous methotrexate, with leucovorin rescue, to treat early multiple sclerosis and other diseases of the central nervous system
JP2004235128A (ja) 2002-12-04 2004-08-19 Dainippon Printing Co Ltd 有機ｅｌ素子およびその製造方法
GB0404487D0 (en) * 2004-02-28 2004-03-31 Protherics Molecular Design Lt Use of enzyme
GB0519391D0 (en) * 2005-09-22 2005-11-02 Aion Diagnostics Ltd Imaging agents
WO2007062403A2 (en) * 2005-11-28 2007-05-31 Vernon D Rowe Compositions useful for reducing nephrotoxicity and methods of use thereof
US7658913B2 (en) * 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
JP4008481B2 (ja) * 2006-08-21 2007-11-14 独立行政法人科学技術振興機構 腎臓の薬物排泄機能に関与する有機アニオントランスポーター

Also Published As

Publication number Publication date
AU2008256808B2 (en) 2013-07-04
US20070270380A1 (en) 2007-11-22
AU2008256808A1 (en) 2008-12-04
BRPI0812166A2 (pt) 2015-07-07
EP2162138A1 (en) 2010-03-17
EP2162138A4 (en) 2010-07-28
CA2687574A1 (en) 2008-12-04
KR20100023901A (ko) 2010-03-04
US20110028413A1 (en) 2011-02-03
US20100093664A1 (en) 2010-04-15
WO2008147856A1 (en) 2008-12-04
US20110027390A1 (en) 2011-02-03
CA2687574C (en) 2016-04-12
US8574551B2 (en) 2013-11-05
EP2162138B1 (en) 2013-08-28
US20120321564A1 (en) 2012-12-20
US8277779B2 (en) 2012-10-02
JP2010528045A (ja) 2010-08-19
CN101686991A (zh) 2010-03-31
US7658913B2 (en) 2010-02-09
AU2008256808A2 (en) 2010-01-07
MX2009012523A (es) 2010-02-18

Similar Documents

Publication Publication Date Title
US8574551B2 (en) Compositions useful for reducing nephrotoxicity and methods of use thereof
US20050164986A1 (en) Use of sulfoalkyl ether cyclodextrin as a preservative
JP2015155462A (ja) 腎毒性の低減に有用な組成物及びその使用方法
JP7597778B2 (ja) シクロデキストリン及びブスルファンを含有する組成物
KR20210107038A (ko) 브라나플람의 경구 제형
HK1125822B (en) Compositions useful for reducing nephrotoxicity and methods of use thereof
KR100771411B1 (ko) 피리미딘-2,4,6-트리온의 시클로덱스트린 포접 복합체
Storm et al. Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130919

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131114

R150 Certificate of patent or registration of utility model

Ref document number: 5416095

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250